Drug loaded peptide brush polymers

A method of treating or managing a condition in a subject comprising:

• administering to a subject an effective amount of a polymer comprising:
• a plurality of repeating units, each repeating unit comprising a polymer backbone group directly or indirectly covalently linked to one or two side chain moieties, the polymer is of formula FX1:
• Q1-[M(Z)u]n-Q2 (FX1);
• wheren:
• n is an integer selected from a range of 2 to 1000;
• u is 1 or 2;
• each M is independently the polymer backbone group of one of the repeating units and each M is independently a ROMP-polymerized monomer;
• each Z is independently one of the one or two side chain moieties (Z) and each Z independently comprises a peptide moiety or a non-peptide therapeutic moiety;
• wherein the polymer comprises a plurality of peptide moieties;
• each Z is independently directly or indirectly covalently attached to an M;
• each M is covalently attached to at least one other M and each M is independently directly or indirectly covalently attached to one or two of Z, such that 100% of the ROMP-polymerized monomers are each individually attached to one or two side chain moieties;
• Q1 is a first polymer-terminating group;
• Q2 is a second polymer-terminating group;
• at least one Z of the polymer comprises a non-peptide therapeutic moiety, Q1 comprises a non-peptide therapeutic moiety, and/or Q2 comprises a non-peptide therapeutic moiety;
• wherein the polymer comprises at least two peptide moieties;
• and
• wherein the at least two peptide moieties include at least two unique peptide moieties.

A method of treating or managing a condition in a subject comprising:

• administering to the subject an effective amount of a liquid composition having water and a plurality of aqueous polymers;
• wherein each of the aqueous polymers independently comprises:
• a plurality of repeating units, each repeating unit comprising a polymer backbone group directly or indirectly covalently linked to one or two side chain moieties, the polymer is of formula FX1:
• Q1-[M(Z)u]n-Q2 (FX1);
• wherein:
• n is an integer selected from a range of 2 to 1000;
• u is 1 or 2;
• each M is independently the polymer backbone group of one of the repeating units and each M is independently a ROMP-polymerized monomer;
• each Z is independently one of the one or two side chain moieties (Z) and each Z independently comprises a peptide moiety or a non-peptide therapeutic moiety;
• wherein the polymer comprises a plurality of peptide moieties;
• each Z is independently directly or indirectly covalently attached to an M;
• each M is covalently attached to at least one other M and each M is independently directly or indirectly covalently attached to one or two of Z, such that 100% of the ROMP-polymerized monomers are each individually attached to one or two side chain moieties;
• Q1 is a first polymer-terminating group;
• Q2 is a second polymer-terminating group;
• at least one Z of the polymer comprises a non-peptide therapeutic moiety, Q1 comprises a non-peptide therapeutic moiety, and/or Q2 comprises a non-peptide therapeutic moiety;
• wherein the polymer comprises at least two peptide moieties;
• and
• wherein the at least two peptide moieties include at least two unique peptide moieties.

A method for synthesizing a polymer, the method comprising steps of:

• ROMP-polymerizing of a plurality of monomers, each monomer being directly or indirectly covalently attached to at least one side chain moiety;
• and
• terminating ROMP-polymerization with a chain termination agent, wherein the chain termination agent comprises a non-peptide therapeutic moiety;
• wherein a synthesized polymer comprises:
• a plurality of repeating units, each repeating unit comprising a polymer backbone group directly or indirectly covalently linked to one or two side chain moieties, the polymer is of formula FX1:
• Q1-[M(Z)u]n-Q2 (FX1);
• where:
• n is an integer selected from a range of 2 to 1000;
• u is 1 or 2;
• each M is independently the polymer backbone group of one of the repeating units and each M is independently a ROMP-polymerized monomer;
• each Z is independently one of the one or two side chain moieties and each Z independently comprises a peptide moiety or a non-peptide therapeutic moiety;
• wherein the polymer comprises a plurality of peptide moieties;
• each Z is independently directly or indirectly covalently attached to an M;
• each M is covalently attached to at least one other M and each M is independently directly or indirectly covalently attached to one or two of Z, such that 100% of the ROMP-polymerized monomers are each individually attached to one or two side chain moieties;
• Q1 is a first polymer-terminating group;
• Q2 is a second polymer-terminating group;
• and
• Q1 comprises a non-peptide therapeutic moiety and/or Q2 comprises a non-peptide therapeutic moiety;
• wherein the polymer comprises at least two peptide moieties;
• and
• wherein the at least two peptide moieties include at least two unique peptide moieties.